A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

730

Participants

Timeline

Start Date

December 6, 2025

Primary Completion Date

September 30, 2031

Study Completion Date

September 30, 2031

Conditions

Small Cell Lung Cancer

Interventions

DRUG

ABBV-706

Intravenous (IV) Infusion

DRUG

Atezolizumab

IV Infusion

DRUG

Etoposide

IV Infusion

DRUG

Carboplatin

IV Injection

DRUG

Carboplatin

IV Infusion

DRUG

Lurbinectedin

IV Infusion